MESOBLAST REPORTS SUBSTANTIAL REVENUE GROWTH TO US$120M RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment Financial Results and Operational Update for Full Year Ended June 30, 2026 New York, USA: August 26 and Melbourne, Australia: August 27, 2026 : Mesoblast Limited ...